Return to homepagePandemic Pact

Augmanity Nano Ltd. is implementing DNA-based technologies and nano-devices to win the battle against the Coronavirus - COVID-19

  • Funded by Israel Innovation Authority
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Israel Innovation Authority

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    Israel

  • Lead Research Institution

    Augmanity Nano

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The company has designed drugs that are particularly targeted for the Coronavirus and have demonstrated that they are capable of effectively and safely destroy the virus' genome. The Biological Institute in Nes Ziona is currently demonstrating the effiency of the drug in cells infected by the virus as part of an agreement signed with the Company and additional laboratories around the world have received the drugs to be used in trials. Augmanity Nano will accelerate the production process and the clinical trials, so the drug can commence trials with Israeli patients this coming summer. Based on the data from these trials, the Company will be able to establish a platform that will provide a quick solution to the outbreak of similar pandemics in the future.